Critical limitations include: Heterogeneity : Different strains, doses, and formulations make comparisons difficult Small effect sizes : Weight changes are typically modest and may not be clinically significant Short duration : Most studies last 12 weeks or less, providing no data on sustained effects Publication bias : Negative studies may be underreported There is no high-quality evidence that probiotic supplements can replicate the substantial weight loss achieved with prescription medications like semaglutide or tirzepatide
Similarly, insurers like Health New England are ending coverage for GLP1 weightloss drugs (Saxenda, Wegovy, Zepbound) for most commercial members as of January 1, 2026, unless their employer buys an optional rider
In the latest episode of NCPDP (National Council for Prescription Drug Programs, Inc.) Unscripted, our VP of Clinical Network Services, Lathe Bigler, joined host Pooja Babbrah to talk about: Why price transparency matters for patient adherence How resilient e-prescribing networks protect continuity of care The importance of real-time benefit data in empowering both prescribers and patients Listen here: At FDB, we believe prescriptions should work like the rest of healthcare consumers experiences: clear, informed, and patient-driven
The traditional approach has been: But more recent evidence and updated practices across UK hospitals show that oral B12 works for many patients , if taken in the right dose and form
We will select the appropriate packaging and the quickest and most cost-effective method for delivering the goods to our customers
